CD117 (c-kit) expression in human hepatocellular carcinoma.

Area of Science:

• Oncology
• Hepatology
• Molecular Biology

Background:

• Advanced hepatocellular carcinoma (HCC) has limited treatment options.
• Platelet-derived growth factor expression in HCC suggests a potential role for c-kit.
• c-kit proto-oncogene is implicated in other solid tumors, including gastrointestinal stromal tumors.

Purpose of the Study:

• To determine the prevalence of c-kit (CD117) overexpression in patients with HCC.
• To evaluate the potential role of imatinib in HCC treatment based on c-kit expression.

Main Methods:

• Retrospective analysis of 258 archival HCC specimens.
• Immunohistochemistry using rabbit anti-CD117 antibody A4502 to assess c-kit expression.

Main Results:

• Overall positive immunohistochemical staining for CD117 was observed in 2.3% (6/258) of HCC cases.
• The low prevalence suggests CD117 is not significantly overexpressed in HCC.

Conclusions:

• CD117 overexpression is not a significant finding in hepatocellular carcinoma.
• These results indicate a limited role for imatinib therapy in HCC treatment based on CD117 expression.